focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

4 Apr 2016 12:59

RNS Number : 0863U
Redx Pharma plc
04 April 2016
 

4 April 2016

REDX PHARMA PLC

("Redx" or "the Company")

 

Grant of options

 

 

Redx, the drug discovery and development company, announces that on 4 April 2016 options over 52,941 ordinary shares of 1p each in the share capital of Company, were granted to Philip Tottey, Chief Financial Officer under Redx's Enterprise Management Incentive Scheme. The options are exercisable at a price of 42.5p, with two-thirds of the options being exercisable immediately and one-third of the shares becoming exercisable on 27 March 2017.

 

For further information please contact:

 

Redx Pharma Plc

T: 0151 706 4747

Neil Murray, Chief Executive

Company website: redxpharma.com

 

 

Cantor Fitzgerald Europe (Nomad & Broker)

T: 020 7894 7000

Phil Davies / Michael Reynolds

 

 

KTZ Communications

T: 020 3178 6378

Katie Tzouliadis/ Viktoria Langley/ Emma Pearson

 

 

 

 

About Redx Pharma Plc

 www.redxpharma.com

 

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary (patent‑protected) drug programs. Six proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMIIMBTMBAMBPF
Date   Source Headline
4th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
3rd Feb 20206:27 pmRNSForm 8.3 - RedX Pharma PLC
3rd Feb 202011:45 amRNSForm 8.5 (EPT/RI)
30th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
28th Jan 20207:00 amRNSStatement re Rule 2.6 Extension
24th Jan 202011:05 amRNSHolding(s) in Company
24th Jan 20209:40 amRNSHolding(s) in Company
23rd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
23rd Jan 20208:32 amRNSForm 8.3 - Redx Pharma plc
22nd Jan 20205:04 pmRNSPaul John Blackmore - Form 8.3 - RedX Pharma
22nd Jan 202012:49 pmRNSForm 8.3 - RedX Pharma PLC
22nd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
21st Jan 20201:23 pmRNSResult of General Meeting
16th Jan 20209:25 amRNSForm 8.3 - Redx Pharma plc
15th Jan 20204:20 pmRNSForm 8.3 - Redx Pharma PLC
15th Jan 20203:17 pmRNSForm 8.3 - Redx Pharma Plc
15th Jan 20202:57 pmRNSForm 8.3 - Redx Pharma plc
10th Jan 20207:56 amRNSForm 8.3 - Redx Pharma plc
9th Jan 20202:14 pmRNSPublic Opening Position Disclosure
9th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
9th Jan 20207:00 amRNSRXC007 nominated as drug development candidate
7th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
6th Jan 20202:16 pmRNSForm 8.3 - Redx Pharma
6th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
3rd Jan 20204:14 pmRNSPosting of Circular to Shareholders
3rd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
2nd Jan 20202:44 pmRNSForm 8.3 - Redx Pharma plc
2nd Jan 202012:57 pmGNWForm 8.3 - AXA INVESTMENT MANAGERS: Redx Pharma PLC
2nd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
31st Dec 20197:00 amRNSLoan Capitalisation, GM Notice and Possible Offer
19th Nov 20197:00 amRNSRedx & Medicines Discovery Catapult awarded grant
7th Nov 20193:30 pmRNSHolding(s) in Company
23rd Sep 20197:00 amRNSRXC006 poster presentation at ERS Congress
19th Aug 20197:00 amRNSFirst cohort of patients dosed in RXC004 study
18th Jul 201910:24 amEQSHardman & Co Research: RedX Pharma (REDX): Pan-RAF agreement strengthens balance sheet
11th Jul 20191:41 pmEQSHardman & Co Research: Redx Pharma (REDX): Phase I trial resumed
10th Jul 20197:00 amRNSSale of pan-RAF inhibitor programme
10th Jun 20197:01 amRNSInterim Results for six months ended 31 March 2019
10th Jun 20197:00 amRNSShort-term Debt Funding Secured
3rd May 201911:34 amRNSUpdate on Plans to Strengthen Balance Sheet
29th Mar 20197:00 amRNSRedx to present two posters at AACR 2019
28th Feb 20197:00 amRNSIssue of Warrants and Change to Lease Agreement
14th Feb 20197:00 amRNSDirectorate Update
12th Feb 20197:00 amRNSNew in vivo data on ROCK2
6th Feb 201911:25 amRNSReceipt of Outstanding Loan
31st Jan 20197:00 amRNSDeinove return rights to Redx Programme
23rd Jan 201911:25 amRNSResults of Annual General Meeting
21st Jan 20197:00 amRNSRXC004 Trial Approval
10th Jan 20192:05 pmRNSSecond Price Monitoring Extn
10th Jan 20192:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.